Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Neuropeptide receptors as entry points for developmental ...

Published by: Elsevier Published by Review article Open access Under a Creative Commons license Article Highlights • Neuropeptides are expressed either transiently or permanently in the developing brain. • Neuropeptides, when applied acutely, can affect growth

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Published by: Elsevier

Published by

Review article

Open access

Under a Creative Commons license

Highlights

  • Neuropeptides are expressed either transiently or permanently in the developing brain.

  • Neuropeptides, when applied acutely, can affect growth cone mobility and directional turning.

  • The redundancy of neuropeptides could create a setpoint for neuronal differentiation through a combinatorial code.

  • Neuropeptide receptors copartitioned toward motile neurite tips with the molecular targets of psychoactive drugs.

  • Psychoactive drugs could thus silence or hijack neuropeptide signaling to adversely impact neuronal wiring decisions.

Traditional views in cellular neurobiology stipulate that neuropeptides, biologically active peptides cleaved from precursor proteins with substantial expression in the nervous system, modulate bidirectional synaptic neurotransmission in the adult brain by engaging mostly, if not exclusively, G protein-coupled receptors. Recent evidence also places neuropeptides into developmental processes, with both transient and permanent expression foci in the fetal nervous system contributing to neuronal fate choices, notably axonal growth and directional guidance. Neuropeptide receptors are partitioned within navigating growth cones, with the bulk of neuropeptides inducing steering decisions, at least in vitro. Thus, any developmental process that disrupts growth cone motility and biases guidance decisions might render neuropeptide signaling inadequate for neuronal circuit formation. We recognize maternal drug abuse during pregnancy as a major liability for neuropeptide signaling, because the most common psychoactive drugs alter neuropeptide levels, their molecular targets coexist with neuropeptide receptors in growth cones, and symptomatically, neuropeptide signaling is altered in neurodevelopmental disorders in children with either prenatal or adolescent drug exposure. Mechanistically, the epigenetic deregulation of neuropeptide expression is suggested. Thus, we propose that neuropeptide-sensitive developmental programs, chiefly neurogenesis and synaptogenesis, are susceptible to psychoactive drugs. Thus, any means to rescue or reinstate neuropeptide signaling could attenuate nervous system pathobiology in offspring passively subjected to substance abuse during pregnancy.

Data availability

No data was used for the research described in the article.

Recommended articles

No articles found.

© 2025 The Author(s). Published by Elsevier Ltd.

P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →